WO2001000184A3 - Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln - Google Patents
Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln Download PDFInfo
- Publication number
- WO2001000184A3 WO2001000184A3 PCT/EP2000/005417 EP0005417W WO0100184A3 WO 2001000184 A3 WO2001000184 A3 WO 2001000184A3 EP 0005417 W EP0005417 W EP 0005417W WO 0100184 A3 WO0100184 A3 WO 0100184A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- medicaments
- mtp inhibitors
- lipid reducers
- reducers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52208/00A AU5220800A (en) | 1999-06-25 | 2000-06-13 | Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19929031.8 | 1999-06-25 | ||
DE19929031A DE19929031A1 (de) | 1999-06-25 | 1999-06-25 | Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001000184A2 WO2001000184A2 (de) | 2001-01-04 |
WO2001000184A3 true WO2001000184A3 (de) | 2001-07-05 |
Family
ID=7912433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/005417 WO2001000184A2 (de) | 1999-06-25 | 2000-06-13 | Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5220800A (de) |
DE (1) | DE19929031A1 (de) |
WO (1) | WO2001000184A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10030375A1 (de) * | 2000-06-21 | 2002-01-03 | Bayer Ag | Verwendung von MTP-Inhibitoren zur Senkung von ppTRL |
DE10200633A1 (de) * | 2002-01-10 | 2003-07-24 | Boehringer Ingelheim Pharma | Kombination von MTP Inhibitoren oder apoB-Sekretions-Inhibitoren mit Fibraten zur Verwendung als Arzneimittel |
ZA200502496B (en) * | 2002-02-28 | 2005-10-12 | Japan Tobacco Inc | Ester compound and medicinal use thereof. |
DE10222034A1 (de) * | 2002-05-17 | 2003-11-27 | Bayer Ag | Tetrahydroisochinolin-Derivate |
WO2003101983A1 (fr) * | 2002-05-31 | 2003-12-11 | Yamanouchi Pharmaceutical Co., Ltd. | Derive tetrahydropyrane |
EP1669345A4 (de) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | Esterderivate und deren medizinische verwendung |
US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023593A1 (en) * | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Apo b-secretion/mtp inhibitory amides |
WO1998050028A1 (en) * | 1997-05-01 | 1998-11-12 | Bristol-Myers Squibb Company | Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels |
-
1999
- 1999-06-25 DE DE19929031A patent/DE19929031A1/de not_active Withdrawn
-
2000
- 2000-06-13 AU AU52208/00A patent/AU5220800A/en not_active Abandoned
- 2000-06-13 WO PCT/EP2000/005417 patent/WO2001000184A2/de active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023593A1 (en) * | 1996-11-27 | 1998-06-04 | Pfizer Inc. | Apo b-secretion/mtp inhibitory amides |
WO1998050028A1 (en) * | 1997-05-01 | 1998-11-12 | Bristol-Myers Squibb Company | Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels |
Also Published As
Publication number | Publication date |
---|---|
DE19929031A1 (de) | 2000-12-28 |
WO2001000184A2 (de) | 2001-01-04 |
AU5220800A (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003239609A1 (en) | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | |
WO2004055006A8 (en) | Novel compounds having selective inhibiting effect at gsk3 | |
AP2003002916A0 (en) | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. | |
IL148288A0 (en) | Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
ZA200108082B (en) | Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth. | |
EP0960621A3 (de) | Pharmazeutische Zusammensetzungen enthaltend sildenafil | |
AU2002328494A1 (en) | Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients | |
HUP0200623A2 (hu) | 4,5-Diaril-3(2H)-furanonszármazékok, mint a ciklooxigenáz-2 inhibitorai és ezeket tartalmazó gyógyszerkészítmények | |
WO2003087050A3 (fr) | Sel de perindopril et les compositions pharmaceutiques qui le contiennent | |
EP1419785A4 (de) | Arzneimittel mit einem chymase-hemmer und einem ace-hemmer als wirkstoffe | |
WO2004000290A8 (en) | Pharmaceutical composition | |
AU2002217464A1 (en) | Medicinal compositions containing aspirin | |
AU2001278821A1 (en) | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | |
WO2005007137A3 (de) | Ambroxolhaltige tabletten | |
AU2924699A (en) | Tryptase inhibitors | |
WO2002034201A3 (fr) | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique | |
AU2003246567A1 (en) | Administration form for the oral administration of active substances, vitamins, and/or nutrients | |
IL143987A (en) | Amidinobenzylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and use of such compositions in the preparation of a medicament for the inhibition of thrombin | |
WO2001000184A3 (de) | Kombination von mtp-inhibitoren und lipidsenkern und ihre verwendung in arzneimitteln | |
WO2002012198A3 (en) | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | |
ZA200110517B (en) | Metalloprotease inhibitors, a process for their preparation and pharmaceutical compositions containing them. | |
WO2001000183A3 (de) | KOMBINATION VON MTP-INHIBITOREN UND HMG-CoA-REDUKTASE-INHIBITOREN UND IHRE VERWENDUNG IN ARZNEIMITTELN | |
WO2002000191A3 (de) | Bdellosomen | |
AU2003246566A1 (en) | Administration form for the oral administration of active substances, vitamins, and/or nutrients | |
AU3825700A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |